skip to Main Content

Plasma Biomarker Helps Distinguish Between Pancreatic Cancer and Chronic Pancreatitis

Newsfeed image, light gray text on dark gray background
Levels of soluble urokinase-type plasminogen activator receptor (suPAR) are higher in plasma of patients with pancreatic cancer (PC) than in patients with chronic pancreatitis (CP), suggesting it may be a useful biomarker for distinguishing between the two diseases.

Plasma suPAR (P-suPAR) is a protein in the blood that reflects immune activation and inflammation. Previous studies have linked urinary suPAR /creatinine ratio level elevation with CP, and elevated P-suPAR elevation with PC. This study aimed to measure P-suPAR levels in CP in a long-term prospective follow-up setting to assess its potential for differentiating CP from PC. Read more . . . 


Back To Top